cr 1392 has been researched along with lorglumide in 2 studies
*lorglumide: RN given refers to (+-)-isomer [MeSH]
*lorglumide: RN given refers to (+-)-isomer [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, S; Fujii, M; Fujisawa, T; Hasegawa, H; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S | 1 |
| Bani, M; Chisté, R; Makovec, F; Revel, L; Rovati, LA; Rovati, LC | 1 |
2 other study(ies) available for cr 1392 and lorglumide
| Article | Year |
|---|---|
Proglumide analogues CR 1409 and CR 1392 inhibit cholecystokinin-stimulated insulin release more potently than exocrine secretion from the isolated perfused rat pancreas.
Topics: Animals; Cholecystokinin; Glutamine; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Pancreas; Proglumide; Radioimmunoassay; Rats; Rats, Inbred Strains | 1990 |
Differentiation of central and peripheral cholecystokinin receptors by new glutaramic acid derivatives with cholecystokinin-antagonistic activity.
Topics: Animals; Benzamides; Cerebral Cortex; In Vitro Techniques; Kinetics; Male; Mice; Pancreas; Proglumide; Rats; Receptors, Cell Surface; Receptors, Cholecystokinin; Sincalide; Tetragastrin | 1986 |